BPC-157 in Australia: Complete Guide (2026)

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protective protein found in human gastric juice. First isolated and studied in the early 1990s by Dr. Predrag Sikiric and colleagues at the University of Zagreb, BPC-157 has been the subject of over 100 published studies investigating its effects on tissue repair, inflammation, and wound healing.

The peptide has gained significant attention in the biohacking and sports recovery communities for its reported effects on tendon, ligament, muscle, and gut healing. It is one of the most researched peptides in the recovery category and consistently ranks among the most searched peptide terms globally.

BPC-157 is classified as a Schedule 4 (Prescription Only) medicine by the TGA when intended for therapeutic use. This means it cannot be legally sold for human consumption without a prescription from an AHPRA-registered medical practitioner.

BPC-157 is not TGA-registered as an approved therapeutic good. It has not undergone the formal evaluation process required for TGA registration. This means no manufacturer can legally market it in Australia as a medicine.

The compound is available from Australian vendors as a research chemical, labelled for research purposes only and not for human consumption. This places it in the regulatory grey area described in our legal guide at /guides/are-peptides-legal-in-australia. Purchasing for personal research use is common but exists in legal ambiguity.

There are two pathways to access BPC-157 in Australia:

Prescription pathway: consult an AHPRA-registered doctor familiar with peptide therapy. If clinically appropriate, the doctor can write a prescription which is then filled by a compounding pharmacy sourcing TGA-licensed ingredients. This is the fully legal pathway but typically costs more than research-grade product.

Research pathway: purchase from an Australian vendor selling BPC-157 for research purposes only. This is the route most individual researchers take. The product is not intended for human consumption per the labelling, though the practical use is widely understood. See our vendor comparison below for rated Australian suppliers.

Two Australian vendors currently carry BPC-157:

Aussie Peptides: BPC-157 10 mg at $89.99 AUD. Currently on pre-order (not in stock at time of writing). Third-party tested, 99%+ purity. Fast domestic shipping across Australia. Use code PEPFYI10 for 10% off your order.

Base Peptides: BPC-157 10 mg at $79.99 AUD. Currently out of stock. University lab tested in Sydney, 99%+ purity. Fast domestic shipping. Use code PEPFYI5 for 5% off your first order.

Both vendors are rated on our vendor comparison page at /vendors with scores across affordability, quality, shipping speed, and customer service. Stock availability changes frequently, so check the vendor websites directly for current status.

BPC-157 pricing in Australia typically ranges from $70 to $120 AUD for a 10 mg vial from domestic vendors. This is a significant markup compared to international sources, which may offer the same quantity for $30 to $50 USD. However, domestic purchasing avoids ABF seizure risk, provides faster delivery (1 to 3 days vs 2 to 4 weeks), and supports vendors with Australian-based quality testing.

Compounding pharmacy pricing through the prescription pathway is typically higher, ranging from $100 to $200 per vial depending on the pharmacy and formulation. This includes pharmaceutical-grade manufacturing and the assurance of TGA-regulated supply chain.

Our free reconstitution calculator at /calculator can help you work out the cost per dose based on the vial size and your chosen dosing protocol.

BPC-157 has been studied extensively in preclinical models (animal studies) for over 30 years. Key findings from the published literature include accelerated healing of tendons, ligaments, and muscle tissue; protective effects on the gastrointestinal tract (gut lining repair); anti-inflammatory properties; and modulation of the nitric oxide system, growth factors (VEGF, EGF), and angiogenesis.

However, there are important caveats that must be acknowledged. There are zero completed human randomised controlled trials for BPC-157 as of 2026. The vast majority of studies come from a single research group (Sikiric et al., University of Zagreb). No independent large-scale replication studies have been published. The peptide is not FDA or TGA approved for any indication.

The research is genuinely promising at the preclinical level, but claiming that BPC-157 is proven to work in humans is not supported by the current evidence base. More independent research and human clinical trials are needed.

Australian interest in BPC-157 is primarily driven by the sports medicine and regenerative medicine communities. Several Australian integrative medicine practitioners are using BPC-157 in clinical settings under the compounding pathway, particularly for tendon and ligament injuries.

Australian universities have not yet published independent BPC-157 studies, but there is growing academic interest in peptide therapeutics generally. The University of Queensland, Monash University, and the University of Sydney all have active peptide research programmes, though focused primarily on other compounds.

The Australian Sports Commission and Sport Integrity Australia monitor BPC-157 closely. It is currently on the WADA monitoring programme but not on the prohibited list. Athletes should check the current status before using BPC-157, as this classification can change.

Is BPC-157 a steroid? No. BPC-157 is a peptide (a short chain of amino acids), not an anabolic steroid. It does not affect testosterone or other steroid hormones.

Can I buy BPC-157 at a pharmacy in Australia? Not directly. BPC-157 is not a TGA-registered medicine and is not stocked by retail pharmacies. It can only be obtained through a compounding pharmacy with a valid prescription.

Is BPC-157 safe? The preclinical safety profile is favourable, with no reported toxicity in animal studies at therapeutic doses. However, human safety data is extremely limited. Common anecdotal reports include mild nausea, dizziness, and injection site reactions. The absence of comprehensive human safety data means the full risk profile is unknown.

How should I store BPC-157? Lyophilised BPC-157 should be stored at minus 20 degrees Celsius for long-term storage or 2 to 8 degrees Celsius for short-term. Once reconstituted, store at 2 to 8 degrees and use within 4 weeks. See our storage guide at /guides/how-to-store-peptides.

This guide is for educational and informational purposes only. It is not intended as medical advice, legal advice, or an endorsement of BPC-157 for human use. BPC-157 is a Schedule 4 (Prescription Only) medicine in Australia when intended for therapeutic use. Always consult a qualified healthcare professional and a legal professional before purchasing or using any peptide compound. The research information presented reflects the published scientific literature and does not constitute a recommendation for use.